GenScript Launches European mRNA Facility in Delft for Global Expansion

GenScript Expands Global mRNA Capabilities with New European Facility

DELFT, Netherlands, March 12, 2026 /PRNewswire/ -- Biotechnology company GenScript has inaugurated its first mRNA production facility in Europe, located in Delft, the Netherlands, marking a key extension of its mRNA platform across the continent.

This new facility strengthens GenScript’s biotechnology foundation in Europe, providing closer proximity and regulatory alignment for regional innovators focused on developing next-gen therapies, vaccines, and biologics.

Paula Río, PhD, from the Hematopoietic Innovative Therapies Unit at CIEMAT/CIBERER/FJD, UAM, noted the advantages, stating, "Having a local GenScript facility in the EU makes a real difference for us. The closer proximity enables more seamless collaboration, faster turnaround times, and reduced shipping delays. Working with a team that's fully aligned with EU regulations and standards strengthens the partnership and makes day-to-day interactions significantly easier."

GenScript, originally founded in New Jersey, USA, continues to expand its global reach by integrating the Delft facility into its network, enhancing speed, regulatory consistency, and operational resilience for its partners.

A Comprehensive mRNA Platform

The new site, part of Europe’s robust life science ecosystem, offers comprehensive mRNA services, including:

• Gene design and synthesis
• Vector engineering
• IVT mRNA production
• Proprietary GenCap™ mRNA capping technology
• UTR optimization and formulation support

Operating under GenScript's AI-driven digital framework, the facility facilitates consistent processes and quicker turnaround times, syncing seamlessly with the company's global R&D and manufacturing network.

Strengthening Global and European Operations

This facility is part of GenScript’s strategic growth, complementing recent expansions at its New Jersey campus and other sites across North America, Europe, and Asia. These initiatives are designed to create resilient platforms supporting life science innovation from discovery to advanced development.

GenScript’s global systems enable the smooth transition of mRNA research into downstream development within the region’s regulatory frameworks.

Commitment to European Innovation

With its European headquarters in the Netherlands since 2021, GenScript has been steadily broadening its regional activities. The Delft site reinforces this commitment, providing local access to advanced mRNA technologies on a global scale.

Cindy Gerhardt, Managing Director of Planet B.io, expressed enthusiasm: "From our first conversations, GenScript has demonstrated a strong commitment to innovation, collaboration, and scientific excellence. We've built a valuable partnership driven by a shared ambition to accelerate biotech research and innovation. The opening of this state-of-the-art lab strengthens the position of the Biotech Campus Delft—not only for our own community, but for the broader European biotech ecosystem."

Sherry Shao, CEO of GenScript Biotech Corporation, emphasized the company’s ongoing global strategy: "This expansion reflects disciplined execution of our global platform strategy. As a U.S.-founded company committed to advancing biotechnology worldwide, we continue to invest in resilient, regionally anchored infrastructure that supports innovation with speed, quality, and trust. At GenScript, 'Scripting Possibilities' means building the integrated global systems that allow science to move confidently from discovery to development, across regions, and at scale."

About GenScript

GenScript Biotech Corporation, launched in 2002, accelerates biotech and healthcare innovations by providing essential components for groundbreaking treatments. As a vital part of the global life science ecosystem, it partners with a diverse network, aiming to co-create solutions that elevate service standards. With over 5,500 employees, GenScript serves more than 200,000 customers in 100+ countries, including the top 20 global pharmaceutical companies.

Media Contact:

Melis Inceer, Head of Integrated Communications & Content
[email protected]
+1 (628) 224-3831

Photo - https://mma.prnewswire.com/media/2932330/GenScript_Biotech_Ribbon_Cutting.jpg

Logo - https://mma.prnewswire.com/media/2855189/GenScript_Logo.jpg